Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar:21:100716.
doi: 10.1016/j.conctc.2021.100716. Epub 2021 Jan 19.

Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol

X Solanich  1 , A Antolí  1 , N Padullés  2 , M Fanlo-Maresma  1 , A Iriarte  1 , F Mitjavila  1 , O Capdevila  1 , M Molina  3 , J Sabater  4 , J Bas  5 , A Mensa-Vilaró  6 , J Niubó  7 , N Calvo  8 , S Bolivar  8 , R Rigo-Bonnin  9 , L Arregui  10 , C Tebé  11 , P Hereu  12   13 , S Videla  12   13 , X Corbella  1   14
Affiliations
Review

Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol

X Solanich et al. Contemp Clin Trials Commun. 2021 Mar.

Abstract

Introduction: Some COVID-19 patients evolve to severe lung injury and systemic hyperinflammatory syndrome triggered by both the coronavirus infection and the subsequent host-immune response. Accordingly, the use of immunomodulatory agents has been suggested but still remains controversial. Our working hypothesis is that methylprednisolone pulses and tacrolimus may be an effective and safety drug combination for treating severe COVID-19 patients.

Methods: and analysis: TACROVID is a randomized, open-label, single-center, phase II trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) versus SoC alone, in patients at advanced stage of COVID-19 disease with lung injury and systemic hyperinflammatory response. Patients are randomly assigned (1:1) to one of two arms (42 patients in each group). The primary aim is to assess the time to clinical stability after initiating randomization. Clinical stability is defined as body temperature ≤37.5 °C, and PaO2/FiO2 > 400 and/or SatO2/FiO2 > 300, and respiratory rate ≤24 rpm; for 48 consecutive hours.

Discussion: Methylprednisolone and tacrolimus might be beneficial to treat those COVID-19 patients progressing into severe pulmonary failure and systemic hyperinflammatory syndrome. The rationale for its use is the fast effect of methylprednisolone pulses and the ability of tacrolimus to inhibit both the CoV-2 replication and the secondary cytokine storm. Interestingly, both drugs are low-cost and can be manufactured on a large scale; thus, if effective and safe, a large number of patients could be treated in developed and developing countries.

Trial registration number: NCT04341038 / EudraCT: 2020-001445-39.

Keywords: COVID-19; Inflammation; Lung injury; Methylprednisolone; SARS-CoV-2; Tacrolimus.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflicts of interest.

References

    1. Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agents. 2020:105924. doi: 10.1016/j.ijantimicag.2020.105924. - DOI - PMC - PubMed
    1. Wang L., Wang Y., Ye D., Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2)based on current evidence. Int. J. Antimicrob. Agents. 2020:105948. doi: 10.1016/j.ijantimicag.2020.105948. - DOI - PMC - PubMed
    1. WHO Director-General's opening remarks at the media briefing on COVID-19. 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re...
    1. Colson P., Rolain J.M., Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV2. Int. J. Antimicrob. Agents. 2020:105923. doi: 10.1016/j.ijantimicag.2020.105923. - DOI - PMC - PubMed
    1. Colson P., Rolain J.M., Lagier J.C., Brouqui P., Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int. J. Antimicrob. Agents. 2020;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. - DOI - PMC - PubMed

Associated data